Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

Withdrawn before enrolling · Phase 1

Conditions studied: Head and Neck Squamous Cell Carcinoma (HNSCC)

In brief

Hypothesis The incidence of toxicity in patients receiving the tumor DNA-transfected fibroblast vaccine will be acceptably low and the immunologic response rate sufficiently high to warrant further study of this therapy The study of the vaccine will proceed in two stages after the method of Simon (102). In the first stage, 15 patients will be accrued and treated. If two or fewer objective immunologic responses occur, the study will be terminated. If 3 or more responses are observed, the study will proceed to the second stage, accruing an additional 22 patients. If the second stage is complete and a total of 9 or more immunologic responses are observed among the 37 patients treated, the treatment response rate for the vaccine will be considered high enough to warrant further study. Conversely, if the evaluation of the vaccine concludes at the first stage, or if 8 or fewer total immunologic responses occur after completing the second stage, the vaccine will not be considered for further study.

Key facts

Study ID

NCT02211027

Run by

Robert Ferris

People needed

0

Starts

2016-09-01

Expected to finish

2028-12-01

Last updated by the study team

2017-09-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathological stage I-IVa HNSCC
• The subject must have a complete removal of the primary HNSCC lesion with negative gross and microscopic margins. Documentation of margins by frozen sections at surgery is recommended. Patients who have already had surgery and have available banked tumor samples can be enrolled AFTER surgery.
• At least 18 years of age.
• Karnofsky performance status >/= 70
• Adequate hematologic function:
• Absolute neutrophil count > 1,000/mm3
• Absolute lymphocyte count > 1,000/mm3
• Hemoglobin > 9 g/dL
• Platelets > 100,000/mm3
• Liver function tests:
• Bilirubin (total) < /=1.7 mg/dL
• Alkaline phosphatase < 252 u/L
• SGOT < 108 u/L
• Kidney profile:
• Serum electrolytes
• Sodium 136-146 mEq/L
• Potassium 3.5-5.0 mEq/L
• Bicarbonate 21-31 mEq/L
• Chloride 98-107 mmol/L
• Serum creatinine < 3 x ULN
• BUN 8-26 mg/dL
• At least a 12 week interval should have elapsed between prior surgery, radiation therapy, chemotherapy or any other treatment and the first vaccination. Patients should have recovered from surgery and adjuvant treatment.
• The effects of the tumor DNA-transfected fibroblast vaccine on the developing human fetus are unknown. For this reason women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 4 months after the last dose of the study vaccine, even if oral contraceptives are used. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of the tumor DNA-transfected fibroblast vaccine administration.

You may not qualify if…

• Patients will be EXCLUDED from participation in the study if any of the following apply:
• One or more of the Inclusion Criteria are not met.
• A significant history or current evidence of cardiac disease including, but not limited to: congestive heart failure, coronary artery disease, angina pectoris, uncontrolled hypertension, serious arrhythmias or myocardial infarction within the previous six months.
• Evidence of ongoing or active infection requiring antibiotic therapy.
• Active intracranial metastases. Patients with previously resected intracranial disease and/or previously irradiated intracranial metastases that have been clinically stable for four weeks are eligible.
• Pregnant or lactating women. Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test per standard of care prior to the surgery for tumor removal. A second pregnancy test must be performed 7 days prior to the first vaccination and must be negative. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated on study.
• Patients requiring systemic corticosteroids (unless patients have had no corticosteroids within 4 weeks prior to start of study).
• Autoimmune disease including, but not limited to, rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, or ankylosing spondylitis.
• Patients who have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the patient has been disease-free for at least 5 years prior to registration.
• Uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements.
• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study. HIV testing will be performed in patients receiving combination anti-retroviral therapy when indicated per medical records review.
• Patients with clinical symptoms of Hepatitis B and/or Hepatitis C will be tested, if clinically indicated per medical records review. Positive results will be an exclusion criteria

Where it is running

• University of Pittsburgh Medical Center Presbyterian Hospital — Pittsburgh, Pennsylvania, United States
• University of Pittsburgh Cancer Institute-Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
• University Of Pittsburgh Medical Center- Shadyside Hospital — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.